Yue Zhi, Chen Wei, Zgurskaya Helen I, Shen Jana
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy , Baltimore, Maryland 21201, United States.
Department of Chemistry and Biochemistry, University of Oklahoma , Norman, Oklahoma 73019, United States.
J Chem Theory Comput. 2017 Dec 12;13(12):6405-6414. doi: 10.1021/acs.jctc.7b00874. Epub 2017 Nov 20.
AcrB is the inner-membrane transporter of an E. coli AcrAB-TolC tripartite efflux complex, which plays a major role in the intrinsic resistance to clinically important antibiotics. AcrB pumps a wide range of toxic substrates by utilizing the proton gradient between periplasm and cytoplasm. Crystal structures of AcrB revealed three distinct conformational states of the transport cycle, substrate access, binding, and extrusion or loose (L), tight (T), and open (O) states. However, the specific residue(s) responsible for proton binding/release and the mechanism of proton-coupled conformational cycling remain controversial. Here we use the newly developed membrane hybrid-solvent continuous constant pH molecular dynamics technique to explore the protonation states and conformational dynamics of the transmembrane domain of AcrB. Simulations show that both Asp407 and Asp408 are deprotonated in the L/T states, while only Asp408 is protonated in the O state. Remarkably, release of a proton from Asp408 in the O state results in large conformational changes, such as the lateral and vertical movement of transmembrane helices as well as the salt-bridge formation between Asp408 and Lys940 and other side chain rearrangements among essential residues. Consistent with the crystallographic differences between the O and L protomers, simulations offer dynamic details of how proton release drives the O-to-L transition in AcrB and address the controversy regarding the proton/drug stoichiometry. This work offers a significant step toward characterizing the complete cycle of proton-coupled drug transport in AcrB and further validates the membrane hybrid-solvent CpHMD technique for studies of proton-coupled transmembrane proteins which are currently poorly understood.
AcrB是大肠杆菌AcrAB - TolC三联体外排复合物的内膜转运蛋白,在对临床上重要抗生素的固有抗性中起主要作用。AcrB利用周质和细胞质之间的质子梯度泵出多种有毒底物。AcrB的晶体结构揭示了转运循环的三种不同构象状态,即底物进入、结合以及挤出或松散(L)、紧密(T)和开放(O)状态。然而,负责质子结合/释放的特定残基以及质子偶联构象循环的机制仍存在争议。在此,我们使用新开发的膜混合溶剂连续恒定pH分子动力学技术来探索AcrB跨膜结构域的质子化状态和构象动力学。模拟结果表明,在L/T状态下,Asp407和Asp408均去质子化,而在O状态下只有Asp408质子化。值得注意的是,O状态下Asp408释放一个质子会导致大的构象变化,如跨膜螺旋的横向和纵向移动以及Asp408与Lys940之间形成盐桥以及关键残基之间的其他侧链重排。与O和L原体之间的晶体学差异一致,模拟提供了质子释放如何驱动AcrB中O到L转变的动态细节,并解决了关于质子/药物化学计量的争议。这项工作朝着表征AcrB中质子偶联药物转运的完整循环迈出了重要一步,并进一步验证了膜混合溶剂CpHMD技术用于研究目前了解甚少的质子偶联跨膜蛋白。